TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04785755
Drug: Hypertonic saline solution
Normalized name: SODIUM CHLORIDE 30 mg in 1 mL TOPICAL LIQUID [Hypertonic Saline Solution Sodium Chloride]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
Study: NCT04785755
Drug: Etilefrine
Normalized name: etilefrine
DrugBank: Etilefrine (DB08985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
Study: NCT01547130
Drug: Normal (0.9%) saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 2L solution at lukewarm temperature (37.2-38.8 degrees Centigrade)consumed as bolus intake (8-16 oz in one to two minutes) alternating with yoga exercises.
Study: NCT01547130
Drug: HalfLytely
Normalized name: HalfLytely and Bisacodyl
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of 2L solution prepared as per manufacturers instructions and sipped until bowel movements are clear.
Study: NCT00843635
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00909766
Drug: BMS-830216
Normalized name: BMS-830216
DrugBank: BMS-830216 (DB14787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 30 mg, once daily, 28 days
Study: NCT00909766
Drug: BMS-830216
Normalized name: BMS-830216
DrugBank: BMS-830216 (DB14787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 100 mg, once daily, 28 days
Study: NCT00909766
Drug: BMS-830216
Normalized name: BMS-830216
DrugBank: BMS-830216 (DB14787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, oral, 300 mg, once daily, 28 days
Study: NCT00909766
Drug: BMS-830216
Normalized name: BMS-830216
DrugBank: BMS-830216 (DB14787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, oral, 600 mg, once daily 28 days
Study: NCT00909766
Drug: BMS-830216
Normalized name: BMS-830216
DrugBank: BMS-830216 (DB14787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, oral, 1200 mg, once daily, 28 days
Study: NCT00909766
Drug: BMS-830216
Normalized name: BMS-830216
DrugBank: BMS-830216 (DB14787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, to be determined, once daily, 28 days
Study: NCT00943293
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.
Study: NCT00943293
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 140 mg/m2 IV on day -2.
Study: NCT00943293
Drug: Campath
Normalized name: Campath
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
Study: NCT02817555
Drug: Epoetin Alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigator will adjust epoetin doses as per the study algorithm during the run-in (every two weeks) and active phases (every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All epoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of epoetin \> 30 000 units weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate.
Study: NCT02817555
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigator will adjust darbepoetin doses as per the study algorithm during the run-in (every two weeks) and active phases(every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All darbepoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of darbepoetin \>150µg weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate.
Study: NCT01213433
Drug: Artesunate-Amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
Study: NCT01243437
Drug: ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * For adults and children aged \> 15 years: 500 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children aged 8-15 years: 15 mg/kg (maximum 500 mg per dose) orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer.
Study: NCT03629756
Drug: Etrumadenant
Normalized name: Etrumadenant
DrugBank: Etrumadenant (DB17506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrumadenant is an A2aR and A2bR antagonist.
Study: NCT00696657
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.1 mg, once weekly, s.c. injection
Study: NCT00696657
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.2 mg, once weekly, s.c. injection
Study: NCT00696657
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.4 mg, once weekly, s.c. injection
Study: NCT00696657
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.8 mg, once weekly, s.c. injection
Study: NCT00696657
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.8 mg with titration, once weekly, s.c. injection
Study: NCT00696657
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.6 mg with titration, once weekly, s.c. injection
Study: NCT00696657
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.2 mg with titration, once daily, s.c. injection
Study: NCT00696657
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.8 mg with titration, once daily, s.c. injection
Study: NCT04473261
Drug: Iodine Complex
Normalized name: Undecoylium chloride iodine complex
DrugBank: Undecoylium chloride iodine complex (DB09377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine Complex capsule (200mg) will be given three times a day
Study: NCT04473261
Drug: Iodine Complex
Normalized name: Undecoylium chloride iodine complex
DrugBank: Undecoylium chloride iodine complex (DB09377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine Complex syrup form (40ml) will be given three times a day
Study: NCT04473261
Drug: Idoine Complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine Complex spray form 2 puffs will be given three times a day
Study: NCT03629756
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
Study: NCT03312777
Drug: Omnitram
Normalized name: Orenitram
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Omnitram tablets overencapsulated
Study: NCT03312777
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol tablet overencapsulated
Study: NCT02046031
Drug: Ginkgolides Meglumine Injection
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg, ivdrip, once.
Study: NCT00206999
Drug: imipramine
Normalized name: Imipramine
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Either 50 mg of imipramine or placebo will be administered to healthy male volunteers
Study: NCT04497662
Drug: KPL-404
Normalized name: Immunoglobulin G4 [222-proline], anti-(human CD40 antigen) (human-Mus musculus monoclonal KPL-404 γ4-chain), disulfide with human-Mus musculus monoclonal KPL-404 κ-chain, dimer
DrugBank: Abiprubart (DB19333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: humanized IgG4 monoclonal antibody
Study: NCT04423926
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle
Study: NCT04423926
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine 1.4mg/m2 (maximum 2mg) d1
Study: NCT01441440
Drug: venlafaxine ER 75 mg/day (fixed dose)
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration
Study: NCT01441440
Drug: venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration
Study: NCT01248234
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 1mg/kg will be given once to put the patient to sleep for surgery.
Study: NCT01248234
Drug: Etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate 0.3mg/kg will be given once to put the patient to sleep for surgery.
Study: NCT01248234
Drug: Propofol and Etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate 0.2mg/kg plus Propofol 0.5mg/kg will be given once to put the patient to sleep for surgery.
Study: NCT02929095
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02929095
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00159744
Drug: Asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asenapine, 3 weeks
Study: NCT00159744
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine, 3 weeks
Study: NCT04769583
Drug: metronidazole based quadriple therapy
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient randomized in QC will be treated by a double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), metronidazole (500 mg x 2 per day) and clarithromycin (500 mg x 2 per day)
Study: NCT01290484
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil oral tablet three times daily
Study: NCT00200525
Drug: apomorphine HCl injection
Normalized name: apomorphine hydrochloride Injectable Product
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01742624
Drug: Advagraf
Normalized name: Astagraf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01742624
Drug: Prograf
Normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01742624
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT00823719
Drug: ofatumumab + DHAP
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg.~DHAP regimen:~dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m\^2/24 hrs continuous on day 1 of dosing cycle; cytarabine - 2 g/m\^2 q12 hrs (2 doses) on day 2 of dosing cycle.
Study: NCT00943319
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily intravenous dosing to target AVC
Study: NCT00943319
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose.
Study: NCT00943319
Drug: Campath
Normalized name: Campath
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times).
Study: NCT03097328
Drug: TAK-228
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-228 works to inhibit or interfere with cellular functions involved in cell growth and survival. TAK-228 specifically targets a type of protein that can make chemicals that trigger cell growth, including cancer cell growth
Study: NCT02932722
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the propofol group receive propofol anesthesia during remote ischemic preconditioning.
Study: NCT02932722
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the sevoflurane group receive sevoflurane anesthesia during remote ischemic preconditioning.
Study: NCT01279538
Drug: bleselumab
Normalized name: Bleselumab
DrugBank: Bleselumab (DB15253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT01803399
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin will be supplied as oblong, dull red film coated tablets of 400 mg strength. Single dose of moxifloxacin 400 mg will be administered orally
Study: NCT00003243
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00615290
Drug: tipranavir
Normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01133210
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage will be a 300mg Maraviroc pill twice a day for 12 weeks
Study: NCT02673593
Drug: DS102
Normalized name: Dexamethasone Sodium Phosphate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02325674
Drug: Metreleptin
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01284322
Drug: Fresolimumab
Normalized name: Fresolimumab
DrugBank: Fresolimumab (DB12396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients
Study: NCT01132573
Drug: entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01132573
Drug: clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00909142
Drug: Bonefos (Clodronate, BAY94-8393)
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in regular clinical practice receiving Bonefos according to local drug information
Study: NCT04318743
Drug: Glepaglutide
Normalized name: Glepaglutide
DrugBank: Glepaglutide (DB14794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-2
Study: NCT01797198
Drug: Gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT01797198
Drug: Repaglinide
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT00631488
Drug: MK-0893
Normalized name: MK-0893
DrugBank: MK-0893 (DB12044)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).
Study: NCT00631488
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
Study: NCT00631488
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).
Study: NCT00631488
Drug: Placebo for MK-0893
Normalized name: MK-0893
DrugBank: MK-0893 (DB12044)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.
Study: NCT00631488
Drug: Placebo for Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
Study: NCT00631488
Drug: Placebo for Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).
Study: NCT04070313
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.
Study: NCT01324505
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme
Study: NCT01031030
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01648608
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane for neoadjuvant chemotherapy
Study: NCT02267863
Drug: APTO-253
Normalized name: APTO-253
DrugBank: APTO-253 (DB17143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APTO-253 will be given in ascending doses starting at 20 mg/m2 until the maximum tolerated dose or recommended dose is reached.
Study: NCT03215264
Drug: hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600-1200mg daily
Study: NCT03215264
Drug: entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-5mg weekly
Study: NCT03215264
Drug: regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 160mg daily
Study: NCT02610556
Drug: Cisplatin 2
Normalized name: CISPLATIN 200MG/VIL (PF) INJ
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles
Study: NCT02610556
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m2, D1 every 3 weeks for 3 cycles
Study: NCT02610556
Drug: Cisplatin 1
Normalized name: cisplatin 1 MG/ML
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles
Study: NCT00166010
Drug: Nesiritide
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard dose of nesiritide which is a loading dose of 1 mcg/kg IV over 30 minutes followed by a nesiritide infusion at 0.01mcg/kg/min. All patients will be continually evaluated. At any time the attending physician may add or adjust treatment if deemed clinically indicated.
Study: NCT01977209
Drug: Gossypol
Normalized name: Gossypol
DrugBank: Gossypol (DB13044)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01815892
Drug: Withdrawal of furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient (previously on furosemide) will have the furosemide stopped for 2 weeks. The interdialytic weight gain, BP and 24 hour urine volume and sodium excretion will be measured
Study: NCT01815892
Drug: furosemide administration
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will receive 120 mgm furosemide daily for 2 weeks and the interdialytic weight gain, BP and 24 hr urine volume and sodium excretion will be measured.
Study: NCT02064439
Drug: ASA
Normalized name: ASA
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg tablet once daily for 12 months